bioAffinity's CyPath Lung to Debut at Cleveland Clinic Lung Cancer Event

The non-invasive test will be showcased at the prestigious annual conference.

Apr. 7, 2026 at 1:43pm

Got story updates? Submit your updates here. ›

An ethereal, ghostly X-ray image of the delicate internal structure of a human lung, rendered in shades of gray and white against a dark background, conceptually representing the innovative technology behind the CyPath Lung cancer detection test.The CyPath Lung test aims to detect early-stage lung cancer through a non-invasive analysis of cells collected from a patient's sputum sample.San Antonio Today

bioAffinity Technologies, a clinical-stage cancer detection and treatment company, announced that its CyPath Lung test will be featured at the upcoming Cleveland Clinic's 'Advances in Early Lung Cancer Detection and Treatment' conference. CyPath Lung is a non-invasive test that uses flow cytometry to detect lung cancer in its early stages.

Why it matters

Early detection is crucial for improving lung cancer survival rates, and CyPath Lung offers a promising non-invasive alternative to invasive biopsy procedures. Presenting at the prestigious Cleveland Clinic event will help raise awareness of this innovative technology among leading lung cancer experts and clinicians.

The details

CyPath Lung analyzes cells collected from a patient's sputum sample to detect the presence of lung cancer. The test has shown high accuracy in clinical trials, with the potential to identify lung cancer at its earliest stages when treatment is most effective. bioAffinity will showcase CyPath Lung and share data on its performance during the Cleveland Clinic conference.

  • The Cleveland Clinic 'Advances in Early Lung Cancer Detection and Treatment' conference is scheduled for May 15-17, 2026.
  • bioAffinity Technologies announced the CyPath Lung presentation on April 7, 2026.

The players

bioAffinity Technologies

A clinical-stage cancer detection and treatment company developing innovative technologies like the CyPath Lung test.

Cleveland Clinic

A renowned academic medical center and one of the top-ranked hospitals in the United States, hosting an annual conference focused on advancements in early lung cancer detection and treatment.

Got photos? Submit your photos here. ›

What’s next

Following the Cleveland Clinic conference, bioAffinity Technologies plans to continue advancing CyPath Lung through additional clinical trials and regulatory approval processes to bring this non-invasive lung cancer detection technology to market.

The takeaway

The inclusion of bioAffinity's CyPath Lung test at the prestigious Cleveland Clinic lung cancer conference underscores the potential of this innovative technology to transform early lung cancer detection and improve patient outcomes.